Latest filing published 12 Aug 2022 for Corbus Pharmaceuticals Holdings, Inc., €1,235.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Craig Stuart Millian: trading record in brief
Craig Stuart Millian (senior executive) discloses dealings in Corbus Pharmaceuticals Holdings, Inc. to SEC (Form 4). Between 14 March 2019 and 10 August 2022, the trades on record add up to 8 filings.
Purchases make up the whole of the open-market record (8 purchases, €68k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2022: 2 purchases and no sales on the market.
A typical purchase (the median) is worth €6,925. On 8 out of 8 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
On 12 August 2022 came the latest disclosure, an open-market purchase for €1,235 in Corbus Pharmaceuticals Holdings, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Craig Stuart Millian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$0.254527.0% of flowCommon StockSEC:0001209191-22-045524:0Canonical exit: 8 Nov 2022 (T+90)
- 10,000 shares@ US$0.3773.0% of flowCommon StockSEC:0001209191-22-018101:0Canonical exit: 8 Jun 2022 (T+90)
2 of 2 declarations